2024
Racial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupOlder patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare accessSecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosisTreatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original Research
2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemiaPatterns of Care for Older Patients With Myelofibrosis: A Population-based Study
Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.Peer-Reviewed Original ResearchConceptsPatterns of careOlder patientsEnd Results-Medicare databaseJAK inhibitor eraHigh-risk patientsPopulation-based studyUse of ruxolitinibJAK inhibitor ruxolitinibUnited States FoodRuxolitinib approvalMedian ageMedian timeTreatment patternsD claimsCurrent treatmentInhibitor ruxolitinibPatientsBetter outcomesClinical experienceDrug AdministrationMedicare Part BMyelofibrosisRuxolitinibStates FoodNew drugsContemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic Advances In Hematology 2021, 12: 20406207211043404. PMID: 35154624, PMCID: PMC8832334, DOI: 10.1177/20406207211043404.Peer-Reviewed Original ResearchChronic phase chronic myeloid leukemiaFrontline tyrosine kinase inhibitorsTyrosine kinase inhibitorsOlder patientsChronic myeloid leukemiaTKI switchingMyeloid leukemiaSecond-generation tyrosine kinase inhibitorsBCR-ABL1 tyrosine kinase inhibitorsTyrosine kinase inhibitor useOlder CML patientsEnd Results-MedicareFavorable safety profileSpecific patient populationsContemporary practice patternsFrontline imatinibTKI choiceGreater comorbidityMost patientsInhibitor usePatient characteristicsWhite patientsDiagnosis yearTKI useCML patients
2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differencesPatterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.Peer-Reviewed Original ResearchConceptsIntensive induction chemotherapyAcute myeloid leukemiaHospital deathInduction chemotherapyAdult patientsMultivariable logistic regression modelLow hospital volumePremier Healthcare DatabasePredictors of deathHealthcare resource utilizationIntensive care unitPatterns of careStandard of careLogistic regression modelsFit patientsRemission inductionFirst hospitalizationHospital volumeInpatient deathInpatient mortalityOlder patientsSupportive careMedian ageAML patientsCare unit
2019
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis
Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis. Cancer 2019, 125: 4241-4251. PMID: 31483484, PMCID: PMC7733320, DOI: 10.1002/cncr.32439.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTime of diagnosisOlder patientsActive treatmentMyeloid leukemiaMultivariable logistic regression modelMedian overall survivalPercentage of patientsLow-intensity therapyMajority of patientsNovel therapeutic optionsQuality of careLogistic regression modelsIntensity therapyTherapy receiptOverall survivalWorse survivalClinical factorsInferior survivalEntire cohortTherapeutic optionsPatient populationRetrospective analysisHigher oddsProvider characteristics
2017
Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life
Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal Of Clinical Oncology 2017, 35: jco.2017.72.714. PMID: 28783450, PMCID: PMC5648174, DOI: 10.1200/jco.2017.72.7149.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDays of lifeEnd of lifeLife careHospice careOlder patientsHospice enrollmentMyeloid leukemiaIntensive care unit admissionMultivariable logistic regression analysisOlder adultsLate hospice enrollmentCare unit admissionRetrospective cohort studyUse of chemotherapyIntensive care unitHealth care useLogistic regression analysisYears of ageUnit admissionAggressive treatmentCohort studyOverall cohortAML diagnosisCare unitHypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.Peer-Reviewed Original ResearchOverall survivalHR-MDSDiagnosis yearUS population-based analysisEnd Results-Medicare dataHigh-risk myelodysplastic syndromeLarge population-based studyConventional care regimensMedian overall survivalRetrospective cohort studyRisk myelodysplastic syndromesPopulation-based studyRecent registry dataPopulation-based analysisUse of decitabineAZA-001Unselected natureCohort studyConventional careExcess blastsOlder patientsTherapy usePatient selectionSurvival prolongationCare regimens121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.Peer-Reviewed Original Research32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s20-s21. DOI: 10.1016/s0145-2126(17)30145-5.Peer-Reviewed Original Research